Aminoxytriphene
![]() | |
| Clinical data | |
|---|---|
| Other names | Amotriphene, Myordil, Win 5494, Rimalcor. |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H29NO3 |
| Molar mass | 403.522 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Amotriphene is a coronary vasodilator that was developed at Sterling Drug in the early 1960s.[1] It has selective binding to alpha-adrenergic receptors.[2]
It has a structure similar to chlorotrianisene (a triphenylethylene), although it is not thought to function as a non-steroidal synthetic estrogen.
References
- ^ Elpern Bill, US3010965 & US3161646 (1961 & 1964 both to Sterling Drug Inc).
- ^ Greenslade FC, Scott CK, Newquist KL, Krider KM, Chasin M (January 1982). "Heterogeneity of biochemical actions among vasodilators". Journal of Pharmaceutical Sciences. 71 (1): 94–100. doi:10.1002/jps.2600710123. PMID 6276530.
- ^ Sandler G (May 1960). "Clinical evaluation of a new coronary vasodilator, 3-dimethylamino-1,1 2-tris (4-methoxyphenyl)-1-propene hydrochloride (WIN 5494)". American Heart Journal. 59 (5): 718–22. doi:10.1016/0002-8703(60)90512-3. PMID 14441425.
- ^ Karczmar AG, Bourgault P, Elpern B (May 1958). "Antiaccelerator, coronary dilator and certain other pharmacologic actions of new poly-methoxyphenyl derivatives". Proceedings of the Society for Experimental Biology and Medicine. 98 (1): 114–8. doi:10.3181/00379727-98-23957. PMID 13554559.
- ^ Day HW (April 1961). "Angina pectoris. A clinical note in the use of Myordil (Win 5494)". The Journal of the Kansas Medical Society. 62: 143. PMID 13720339.
- ^ Ruskin A (May 1961). "Effects of erythrol tetranitrate and amotriphene on exercise tolerance tests in angina pectoris". Circulation. 23 (5): 681–4. doi:10.1161/01.cir.23.5.681. PMID 13744809.
- ^ Harris R (December 1961). "Clinical observations of amotriphene hydrochloride". New York State Journal of Medicine. 61: 4009–14. PMID 13904871.
